Loading organizations...
Partners Innovation Fund operates as an early-stage venture capital entity, channeling investment into transformative medical systems, therapies, drugs, and medical devices. It focuses on translating nascent scientific discoveries and technological advancements from within its institutional framework into viable commercial applications. The fund strategically deploys capital to accelerate the development of solutions with the potential to significantly impact healthcare delivery and patient outcomes.
The fund was established in 2008 by Partners HealthCare, now known as Mass General Brigham. The foundational insight behind its creation was to harness the extensive intellectual and financial capital resident within the healthcare system to drive internal innovation. This initiative aimed to bridge the gap between academic research and commercialization, ensuring that promising discoveries originating from its affiliated hospitals and research centers could receive dedicated support and resources to mature.
Serving its parent institution's extensive research community, the fund's investments ultimately aim to benefit patients by bringing novel medical solutions to market. Its long-term vision centers on fostering a dynamic ecosystem where groundbreaking biomedical research is systematically nurtured and propelled forward. By investing in early-stage projects, Partners Innovation Fund seeks to ensure continuous advancement in medical science and patient care.
Key people at Partners Innovation Fund.
Key people at Partners Innovation Fund.
Partners Innovation Fund has more than 26 tracked investments across 19 companies. The latest tracked deal is $52.0M Series A Extension in SwanBio Therapeutics in April 2020.